Intestinal Akkermansia Muciniphila Predicts Clinical Response to PD-1 Blockade in Patients with Advanced Non-small-cell Lung Cancer

Aside from PD-L1 expression, biomarkers of response to immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer (NSCLC) are needed. In a previous retrospective analysis, we documented that fecal Akkermansia muciniphila (Akk) was associated with clinical benefit of ICI in patients with NSCLC or kidney cancer. In the current study, we performed shotgun-metagenomics-based microbiome profiling in a large cohort of patients with advanced NSCLC (n = 338) treated with first- or second-line ICIs to prospectively validate the predictive value of fecal Akk. Baseline stool Akk was associated with increased objective response rates and overall survival in multivariate analyses, independent of PD-L1 expression, antibiotics, and performance status. Intestinal Akk was accompanied by a richer commensalism, including Eubacterium hallii and Bifidobacterium adolescentis, and a more inflamed tumor microenvironment in a subset of patients. However, antibiotic use (20% of cases) coincided with a relative dominance of Akk above 4.8% accompanied with the genus Clostridium, both associated with resistance to ICI. Our study shows significant differences in relative abundance of Akk that may represent potential biomarkers to refine patient stratification in future studies.

Citing Articles

Gut microbiota therapy in gastrointestinal diseases.

Ullah H, Arbab S, Chang C, Bibi S, Muhammad N, Rehman S Front Cell Dev Biol. 2025; 13:1514636.

PMID: 40078367 PMC: 11897527. DOI: 10.3389/fcell.2025.1514636.

Gut dysbiosis conveys psychological stress to activate LRP5/β-catenin pathway promoting cancer stemness.

Cui B, Luo H, He B, Liu X, Lv D, Zhang X Signal Transduct Target Ther. 2025; 10(1):79.

PMID: 40038255 PMC: 11880501. DOI: 10.1038/s41392-025-02159-1.

Akkermansia muciniphila: promises and pitfallsfor next-generation beneficial microorganisms.

Liu Y, Li Z, Lee S, Chen S, Li F Arch Microbiol. 2025; 207(4):76.

PMID: 40032707 DOI: 10.1007/s00203-025-04263-w.

Big lessons from the little in hepatocellular carcinoma.

Yang Y, Shi X Front Immunol. 2025; 16:1524563.

PMID: 40028328 PMC: 11868108. DOI: 10.3389/fimmu.2025.1524563.

Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients.

Grenda A, Iwan E, Kuznar-Kaminska B, Bomba A, Bielinska K, Krawczyk P Sci Rep. 2025; 15(1):6139.

PMID: 39979394 PMC: 11842579. DOI: 10.1038/s41598-025-89406-1.

References

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Gandhi L, Rodriguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F . Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22):2078-2092. DOI: 10.1056/NEJMoa1801005. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View

Gadgeel S, Rodriguez-Abreu D, Speranza G, Esteban E, Felip E, Domine M . Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2020; 38(14):1505-1517. DOI: 10.1200/JCO.19.03136. View

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L . Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol. 2018; 4(11):1543-1552. PMC: 6248085. DOI: 10.1001/jamaoncol.2018.3676. View

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

10.

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

11.

Spranger S, Bao R, Gajewski T . Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity. Nature. 2015; 523(7559):231-5. DOI: 10.1038/nature14404. View

12.

Smyth M, Ngiow S, Ribas A, Teng M . Combination cancer immunotherapies tailored to the tumour microenvironment. Nat Rev Clin Oncol. 2015; 13(3):143-58. DOI: 10.1038/nrclinonc.2015.209. View

13.

Koyama S, Akbay E, Li Y, Herter-Sprie G, Buczkowski K, Richards W . Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat Commun. 2016; 7:10501. PMC: 4757784. DOI: 10.1038/ncomms10501. View

14.

Young A, Ngiow S, Barkauskas D, Sult E, Hay C, Blake S . Co-inhibition of CD73 and A2AR Adenosine Signaling Improves Anti-tumor Immune Responses. Cancer Cell. 2016; 30(3):391-403. DOI: 10.1016/j.ccell.2016.06.025. View

15.

Chen D, Mellman I . Elements of cancer immunity and the cancer-immune set point. Nature. 2017; 541(7637):321-330. DOI: 10.1038/nature21349. View

16.

Derosa L, Routy B, Desilets A, Daillere R, Terrisse S, Kroemer G . Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discov. 2021; 11(10):2396-2412. DOI: 10.1158/2159-8290.CD-21-0236. View

17.

Routy B, Le Chatelier E, Derosa L, Duong C, Alou M, Daillere R . Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2017; 359(6371):91-97. DOI: 10.1126/science.aan3706. View

18.

Vetizou M, Pitt J, Daillere R, Lepage P, Waldschmitt N, Flament C . Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015; 350(6264):1079-84. PMC: 4721659. DOI: 10.1126/science.aad1329. View

19.

Gopalakrishnan V, Spencer C, Nezi L, Reuben A, Andrews M, Karpinets T . Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2017; 359(6371):97-103. PMC: 5827966. DOI: 10.1126/science.aan4236. View

20.

Derosa L, Zitvogel L . Antibiotics impair immunotherapy for urothelial cancer. Nat Rev Urol. 2020; 17(11):605-606. DOI: 10.1038/s41585-020-0373-1. View